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Correlation of FDG uptake and glucose transporter type 1 
expression between primary tumors and loco-regional lymph nodes 
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Purpose: FDG uptake in the primary tumors and malignant lymph 
nodes of NSCLC has been reported to be mediated by glucose trans-
porter type 1 (glut-1). The level of FDG uptake in primary tumors may 
affect the likelihood of malignant involvement in the loco-regional 
lymph nodes. Therefore, we investigated the correlation of FDG uptake 
and glut-1 expression between primary tumors and loco-regional lymph 
nodes of NSCLC.
Methods: One hundred twenty-six NSCLC patients (male:fe-
male=103:23, age=65±9.7y) who had underwent curative resec-
tions and loco-regional lymph node dissections within 4 weeks after 
FDG-PET study were enrolled. Maximum standardized uptake values 
(maxSUV) on PET and glut-1 expression percentages on surgical speci-
mens were measured and compared between primary tumors and FDG 
uptake positive loco-regional lymph nodes. 
Results: After excluding the peribronchial lymph nodes directly 
invaded by primary tumors and the benign lymph nodes with no FDG 
uptake, 126 primary tumors and 196 loco-regional lymph nodes (52 
malignant and 144 benign) were analyzed. Fifty-two malignant lymph 
nodes were compared with 37 primary tumors. There were signiﬁcantly 
high correlations of maxSUV (r=0.6399, p<0.0001) and percentage of 
glut-1 expression (n=15, r=0.8193, p=0.0002) between primary tumors 
and malignant lymph nodes. Linear regression equation between 
maxSUV of malignant lymph nodes (Y) and maxSUV of primary 
tumors (X) was expressed as Y = 0.6891 + 0.4679 X. To the contrary, 
144 benign lymph nodes were not correlated with 75 primary tumors in 
terms of maxSUV (r=-0.0125, p=0.8831) and glut-1 (n=19, r=0.3876, 
p=0.1010) expression. 
Conclusions: Primary tumors of NSCLC had high correlations of FDG 
uptake and glut-1 expression with malignant lymph nodes but not with 
benign lymph nodes. Mediastinal lymph node staging of NSCLC by 
FDG-PET may be improved by considering the correlation of FDG 
uptake and glut-1 expression between primary tumors and malignant 
lymph nodes
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Preoperative staging procedures using 18F-FDG-Positron Emission 
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findings in Malignant Pleural Mesothelioma undergoing 
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Background: Extrapleural pneumonectomy (EPP) in MPM may be 
conﬁned with both morbidity and mortality and careful preoperative 
staging identifying respectable patients is important. Staging is difﬁcult 
and the accuracy of preoperative CT-scan, 18F-FDG-PET-CT-scan 
fused imaging (PET-CT), and mediastinoscopy is unclear. The objec-
tives were to compare these staging techniques to each other and to 
surgical-pathological ﬁndings.
Methods: Patients had epithelial subtype MPM, age ≤ 70 years, and 
lung function test allowing pneumonectomy. Preoperative staging after 
3-6 courses of induction chemotherapy included conventional CT-scan, 
PET-CT, and mediastinoscopy. Surgical-pathological ﬁndings were 
compared to preoperative ﬁndings.
Results: 42 consecutive patients were without T4 or M on CT-scan. 
PET-CT showed inoperability in 12 patients (29%) due to T4 (7 
patients) and M1 (7 pts). Among 30 patients with subsequent mediasti-
noscopy, including 10 with N2/N3 on PET-CT, N2 were histologically 
veriﬁed in 6 (14%). Among 24 resected patients, T4 occurred in 2 
patients (8%), and N2 in 4 (17%), all being PET-CT negative. PET-CT 
accuracy of T4 and N2/N3 compared to combined histological results 
of mediastinoscopy and EPP showed sensitivity, speciﬁcity, pos. pre-
dictive value, neg. predictive value, and pos. and neg. likelihood ratios 
of 78% and 50%, 100% and 75%, 100% and 50%, 94% and 75%, not 
applicable and 5.0, and 0.22 and 0.67, respectively. 
Conclusions: Non-curative surgery is avoided in 29% out of 42 MPM 
patients by preoperative PET-CT and in further 14% by mediastinosco-
py. Even though both procedures are valuable, there are false negative 
ﬁndings with both, urging for even more accurate staging procedures.
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Purpose: to determine prospectively whether the standardized uptake 
value (SUV) of ﬂuorodeoxyglucose uptake by positron emission to-
mography (FDG-PET) could be a prognostic factor for refractory non-
small-cell lung cancer NSCLC treated with erlotinib. To prospectively 
evaluate the use of (FDG-PET) on response evaluation to erlotinib.
Patients and Methods: Patients with histologically proven NSCLC 
pretreated with chemotherapy, undergo palliative erlotinib 150 mg/die 
were eligible for this study. Patients were evaluated by FDG-PET 
before erlotinib and after 45 days of therapy: A decrease of 20% or 
more in tumor FDG uptake as measured by standardized uptake value 
(SUV) was deﬁned as a metabolic response. Radiologic response was 
evaluated by CT scan according to RECIST criteria after 60 days of 
treatment .
Results: From September 2006 to February 2007, 16 patients have 
been included in this study. Patients characteristics were as follows: 
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median age 65 yrs (range 23-78), male 12 pts, adenocarcinoma 7 pts, 
second-line erlotinib 10 pts, non-smokers 5 pts. Response assessment 
with clinical and/or conventional radiological methods showed 1 partial 
response (PR), 10 progression (PD), 2 stable disease (SD). Three pts 
were too early for response evaluation in this analysis. Overall disease 
control was 23%. All patients were evaluated with FDG-PET before 
erlotinib: mean maximum SUV (SUV-max) and SUV tumor/liver ratio 
was 9 (range 3,5-15) and 5 respectively. Six patients were assessable 
for response with FDG-PET that showed 1 PR, 2 SD and 3 PD. One 
patient with SD on FDG-PET had progression on CT-scan whereas 1 
pt with PD on FDG-PET had SD on CT-scan. As today the follow-up is 
too short to establish the prognostic value of FDG-PET (SUV and SUV 
ratio) in this subset of patients. Accrual is still ongoing and mature 
results will be presented at the XII world conference on lung cancer
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Evaluation of pulmonary tumors with PET/CT
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Background: F18-FDG PET/CT provides morphologic and metabolic 
information for diagnosis of malignant disease; however, increased glu-
cose uptake is not exclusive of cancer. We analyzed PET/CT capacity 
to study pulmonary tumors in Chilean population. 
Methods: 204 patients with solitary pulmonary tumors were prospec-
tively included in the study, 91 males, mean age 63.2 years (27-96). 
Exams were performed in a PET-CT Scanner Siemens Biograph 6. We 
studied the group with biopsy and/or follow up longer than 6 months, 
153 of the 204 fulﬁlled this requirements. 66 patients had nodules of 
less than 30 mm and 87 had masses between 31 and 120 mm. Based on 
radiological appearance and metabolic activity in PET/CT, lesions were 
classiﬁed in malignant (112), benign (30) and indeterminate (11).
Results: Malignancy was demonstrated in 106 of 112 lesions catego-
rized as malignant by PET/CT (94.6%); 6 false positive results were 
due to 4 infectious/inﬂammatory lesions and 2 benign carcinoid tumors. 
In the group considered as benign, 3 malignant lesions were demon-
strated by biopsy (10%, 2 metastasis of colorrectal cancer, 1 of thyroid 
cancer). In the indeterminate lesions group, 4 of 11 resulted malignant 
(36.3%, 2 lung cancer, 1 metastasis of kidney cancer and 1 of colic 
cancer). Median SUV Max was 10.5 (1.8-35.9) in the malignant group, 
1.0 (0.3-15.3) in the benign group, and 2.0 g/ml (0.7-5.3) in the indeter-
minate group. Difference on SUV of malignant and benign lesions was 
signiﬁcant. 
Positive predictive value (PPV) for malignancy in the malignant group 
was 94.6%. Malignant lesions were found in the 36.3% of the indeter-
minated group and in the 10% of the benign group. 
Conclusion: F18-FDG PET/CT is a reliable method for the study of 
pulmonary lesions, with a 94.6% positive predictive value for malig-
nancy and 90% of negative predictive value. In the indeterminated 
cases histological study is necessary a (33.6% of malignancy).
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Preoperative serum Cyfra 21-1 and CEA help to assess the stage of 
non-small cell lung cancer before surgery
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Background: Staging procedures before surgical treatment of non-
small cell lung cancer (NSCLC) usually consist of chest CT scan, 
upper abdomen CT scan or abdomen ultrasound examination, and brain 
CT scan in selected individuals. The clinical suspicion of mediastinal 
lymph nodes involvement (N2 disease) is the indication for mediasti-
noscopy. The aim of the present study was to assess whether preopera-
tive Cyfra 21-1 or CEA serum measurement could help to predict the 
extension of NSCLC before surgery.
Methods: 49 patients (pts), 38 men, 11 women, median age 65 (42-81) 
years referred to the Department of Thoracic Surgery entered this study. 
Mediastinoscopy was performed in 14 pts, lymph node metastases 
were found in 5 pts (further treated with neoadjuvant chemotherapy). 
Primary surgical treatment was performed in 44 pts. Pathologic stage 
of disease was Ia-IIb in 37 pts and IIIa-IV in 7 pts. Cyfra 21-1 and CEA 
were measured with Elecsys Roche in sera collected before any surgi-
cal procedure. 
Results: Cyfra 21-1 values exceeding 3.3 ng/ml were found in 9/37 
pts with stage Ia-IIb and 8/12 pts with stage IIIa-IV (p=0.03). Median 
Cyfra 21-1 value was 1.93 (0.7-7.6) ng/ml in the pts with Ia-IIb stage 
of disease and 4.6 (1.0-14.5) ng/ml in others (p=0.04). 
Median CEA value was 2.59 (0.87-30.9) ng/ml in the pts with stage 
Ia-IIb and 3.17 (0.76-144.2) ng/ml in other pts (nonsigniﬁcant). Median 
CEA value was 13.8 (0.76-144.2) ng/ml in the group of pts with posi-
tive result of mediastinoscopy and 2.6 (1.0-4.81) ng/ml in those with 
negative mediastinoscopy (p=0.0001). 
Conclusion: Serum Cyfra 21-1 elevation before surgery of NSCLC 
may indicate higher pathologic stage of disease, elevated serum CEA is 
possibly predictive for N2 disease, found on mediastinoscopy. 
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Evaluation of FDG-PET/CT for lung cancer and lymph nodes 
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Background: Fluorodeoxyglucose-Positron Emission Tomography/
Computed Tomography (FDG-PET/CT) is useful for the diagnosis of 
lung cancer. Accurate diagnosis of pulmonary nodule and lymph node 
metastasis contribute to the decision of treatment. 
Materials and Methods: 324 patients with suspected lung cancer 
was performed FDG-PET/CT Ninety-one tumors of 89 patients 70 
male, 19 female, mean age; 67.7years) were diagnosed histologically 
at Tokushima University Hospital from December 2005 to November 
2006. Standardized uptake value max (SUVmax) was used for evalu-
ation of FDG uptake at early phase and delay phase, and Retention 
Index (RI) was calculated in (SUVmax at delay phase- SUVmax at 
early phase) / SUVmax at early phase X 100 (%). We retrospectively 
